Lineage Cell Therapeutics, Inc. (LCTX) vs MacroGenics, Inc. (MGNX)
Lineage Cell Therapeutics, Inc. and MacroGenics, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and MacroGenics, Inc. are of similar size ($242.1M and $239.7M). MacroGenics, Inc. grew revenue faster over the last twelve months: 21.9% against 19.9%. MacroGenics, Inc. has the higher net margin (−7.97% vs −246.6%) and the higher return on invested capital (0.00% vs −186.8%). Across the 18 metrics below, MacroGenics, Inc. leads on 12 and Lineage Cell Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | LCTX | MGNX | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.46% | 78.07% | 65.16% |
| Operating margin | (205.23%) | (18.73%) | 0.00% |
| Net margin | (246.58%) | (7.97%) | 0.00% |
| Free cash flow margin | (186.43%) | (35.80%) | 0.00% |
| Return on equity | (60.35%) | (32.61%) | (57.72%) |
| Return on assets | (32.75%) | (4.94%) | (49.22%) |
| Return on invested capital | (186.79%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack